Advances in clinical research on C1q nephropathy.
- Author:
Juan YANG
1
;
Bi-Li ZHANG
Author Information
1. Department of Nephrology, Tianjin Children's Hospital, Tianjin 300074, China. zhangbili218@163.com.
- Publication Type:Journal Article
- MeSH:
Complement C1q;
metabolism;
Diagnosis, Differential;
Glomerulonephritis;
diagnosis;
drug therapy;
etiology;
Glucocorticoids;
therapeutic use;
Humans;
Prognosis
- From:
Chinese Journal of Contemporary Pediatrics
2016;18(11):1194-1198
- CountryChina
- Language:Chinese
-
Abstract:
C1q nephropathy is a rare type of glomerulonephritis manifested as the deposition of C1q in the glomerular mesangium during immunofluorescent staining. Systemic lupus erythematosus and type I membranoproliferative glomerulonephropathy need to be excluded in the diagnosis of C1q nephropathy. C1q nephropathy has various manifestations under a light microscope, mainly including minimal change disease, focal segmental glomerulosclerosis, and proliferative glomerulonephritis. This disease is mainly manifested as persistent proteinuria or nephrotic syndrome and occurs more frequently in boys. Currently, glucocorticoids are mainly used for the treatment of this disease. Patients with C1q nephropathy show a good response to immunosuppressant treatment, but have a high rate of glucocorticoid resistance. Therefore, in this case, methylprednisolone pulse therapy or a combination with immunosuppressant treatment helps to achieve a good prognosis.
